Company LAUNXP Biomedical Co., Ltd

Launxp Biomedical Co Ltd is a Taiwan-based company mainly engaged in the development of new drugs. The Company mainly develops cancer drugs. The main products include LXPA1788, LXPA1988, LXPA5948, LXPB5268, LXPB5101, LXPB8101, LXPB9568, LXPB977 and others. LXPA1788 is a new ingredient and new drug, a multi-target kinase inhibitor. LXPA1988 is a new ingredient and new drug with a novel chemical structure. It exhibits high inhibitory activity against the fms-like tyrosine kinase 3 (FLT3) kinase and its mutations, inhibiting FLT3 signaling in acute myeloid leukemia (AML) cancer cells and thereby inhibiting tumor growth. LXPA5948 is a new ingredient and new drug. LXPB5268 is a new drug for new indications. LXPB5101, LXPB8101, LXPB9568, and LXPB977 are new drugs with new indications and new dosage forms.